Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Time
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(37)
•••
Comment by PlaySafeon Aug 12, 2021 6:47pm
170 Views
Post# 33698496

RE:RE:RE:RE:RE:RE:RE:RE:RE:Time

RE:RE:RE:RE:RE:RE:RE:RE:RE:Time@Calgary ATE thanks for the link and I'm glad to see that Joe has a game plan to try and address the placebo-effect which in great to hear.  Fingers crossed that his placebo-effect strategy is effective and that the lower dose is statistically effective on a shorter duration Phase 2 trial..

Just to be clear, if Antibe proves that the lower dose is statistically effective as a primary result along with the mobility secondary result then in my mind there are much fewer concerns with a Phase 3 trial being successful and the sky is the limit for Antibe. I also feel that  if 75mg per day works then, in my opinion, BP with buyout Antibe and we won't have to go to Phase 3 and anyone that has Antibe stock will do very very well and you won't care what the price of the stock is right now.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities